Cantor Fitzgerald upgraded Regeneron (REGN) to Overweight from Neutral with a price target of $695, down from $800, as the analyst took over ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: BofA Securities 2025 Health Care Conference at 10:00 a.m. PT (1:00 p.m. ET) on Tuesday, May 13, ...

Oppenheimer keeps an Outperform rating on Regeneron (REGN) with a $925 price target after the FDA denied the company’s attempt to extend the ...

Pharmaceuticals announced on Friday the Food and Drug Administration has issued a complete response letter regarding the ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Regeneron (REGN – Research Report) and Surgery ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter ...